Claims
- 1. A method for immunizing a human against herpes simplex virus (HSV) infection comprising vaccinating the human with an adjuvant and a vaccine formulation consisting essentially of HSV polypeptides wherein the polypeptides are:
- (a) immunogenic;
- (b) glycosylated; and
- (c) consist of:
- (i) a HSV glycoprotein B polypeptide or a HSV glycoprotein B polypeptide that has a deletion of all or a portion of the transmembrane anchor region; and
- (ii) a HSV glycoprotein D polypeptide or a HSV glycoprotein D polypeptide that has a deletion of all or a portion of the transmembrane anchor region;
- and further wherein the immunizing being done is prior to a primary infection with HSV.
- 2. A method for immunizing a human against herpes simplex virus (HSV) infection comprising vaccinating the human with a vaccine formulation consisting essentially of HSV polypeptides, a pharmacologically acceptable medium and an adjuvant, wherein the polypeptides are:
- (a) immunogenic;
- (b) glycosylated; and
- (c) consist of:
- (i) a HSV glycoprotein B polypeptide or a HSV glycoprotein B polypeptide that has a deletion of all or a portion of the transmembrane anchor region; and
- (ii) a HSV glycoprotein D polypeptide or a HSV glycoprotein D polypeptide that has a deletion of all or a portion of the transmembrane anchor region;
- and further wherein the immunizing being done is prior to a primary infection with HSV.
- 3. The method according to claim 2, wherein the polypeptides are recombinantly expressed.
- 4. The method according to claim 2, wherein the glycoprotein B is a Type 1 glycoprotein B and the glycoprotein D is a Type 1 glycoprotein D.
- 5. The method according to claim 2, wherein the glycoprotein B is a Type 1 glycoprotein B and the glycoprotein D is a Type 2 glycoprotein D.
- 6. The method according to claim 2, wherein the glycoprotein B is a Type 2 glycoprotein B and the glycoprotein D is a Type 1 glycoprotein D.
- 7. The method according to claim 2, wherein the glycoprotein B is a Type 2 glycoprotein B and the glycoprotein D is a Type 2 glycoprotein D.
- 8. The method according to claim 2, wherein the glycoprotein B is a Type 1 and a Type 2 glycoprotein B and the glycoprotein D is a Type 1 and a Type 2 glycoprotein D.
- 9. The method according to claim 2, wherein the polypeptides include an anchor sequence.
- 10. The method according to claim 2, wherein the polypeptides are substantially free of an anchor sequence.
- 11. The method according to claim 2, wherein the adjuvant is selected from the group consisting of alum, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (nor-MDP), and N-acetylmuramyl-L-alanyl-D-isoglutaminly-L-alanine-2-(1'2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE).
- 12. The method according to claim 2, wherein the adjuvant is formulated in a low oil formulation.
- 13. The method according to claim 2, wherein at least one of the immunogenically active polypeptides and the adjuvant are encapsulated in a liposome.
CROSS-RELATED TO RELATED APPLICATIONS
This application is a continuation of prior application Ser. No. 07/990,919 filed on 15 Dec. 1992, abandoned, which is a continuation of application Ser. No. 07/416,425, filed 2 Oct. 1989 and issued as U.S. Pat. No. 5,171,568, which is a continuation of application Ser. No. 07/079,605, filed 29 Jul. 1987, abandoned, which is a continuation-in-part of application Ser. No. 06/921,213, filed 20 Oct. 1986, abandoned, which is a continuation-in-part of application Ser. No. 06/597,784, filed 6 Apr. 1984, abandoned, and a continuation-in-part of application Ser. No. 06/631,669, filed 17 Jul. 1984 and issued as U.S. Pat. No. 4,618,578.
US Referenced Citations (14)
Foreign Referenced Citations (3)
Number |
Date |
Country |
0100521 |
Feb 1984 |
EPX |
0133063 |
Feb 1985 |
EPX |
135841 |
Apr 1985 |
EPX |
Continuations (3)
|
Number |
Date |
Country |
Parent |
990919 |
Dec 1992 |
|
Parent |
416425 |
Oct 1989 |
|
Parent |
79605 |
Jul 1987 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
921213 |
Oct 1986 |
|
Parent |
597784 |
Apr 1984 |
|